Hovione expansion provides integrated full-service solution
Hovione's new R6d building in Lisbon.
Additional capacity expansion across several of the company's sites also strengthens the company's global market leadership in spray drying.
Hovione has announced recent capacity expansion and future plans in its sites in Portugal, Ireland and New Jersey, with the aim to increase capacity in existing technologies, such as spray drying and to grow in new areas of business to support client demand.
The capacity expansion program, which started in 2016, will continue during the next 5 years. The first 2 years saw Hovione relocate its development services to a new 7000 m2 centre in Lisbon, 15 minutes away from the Loures manufacturing site. The new Lisbon site is fully equipped to handle potent and highly potent compounds, and hosts 200 scientists specialising in chemistry, particle engineering, formulation and analytical development.
During this period, the Loures site expanded its drug substance reaction vessel capacity with a small-scale production area and a new pilot plant, totalling an extra 30 m3 of capacity. In addition, one pilot and two large-scale spray dryers were installed at the site and started the operation of a new drug product centre equipped with oral dosage form and inhalation manufacturing capabilities.
During the same time, Hovione doubled the size of its development and manufacturing operations in the New Jersey site, providing it with a full range of capabilities, from chemical and analytical development, through spray drying to formulation. The site now hosts 14 m3 of reaction vessel capacity with four independent trains, a pilot and a large scale spray dryer, and a continuous tableting unit.
At the Cork site, Hovione is reinstating and renewing a production building with 157 m3 of chemical synthesis capacity devoted to contract manufacturing. About half of this capacity will be ready for operation by May 2018.
During the next 3 years, Hovione will add to the Loures site a new chemical synthesis and spray dryer building for contract manufacturing, with a total area of 4,200 m2 for 165 m3 of reaction vessel capacity and two large spray drying units, new formulation facilities, which will enable the production of bigger batch sizes, and a new building that will host an additional 1200 m2 of analytical laboratories.
This investment is being paired with recruiting and training new staff, as illustrated by the company's 39% headcount growth in the last 2 years.
“This addition in capacity expansion will secure our growth and ensure that we continue to provide a truly integrated full-service solution to our customers, as well as showing Hovione’s strategy and commitment to further strengthen its global market leadership in spray drying,” said Frédéric Kahn, Vice-President Marketing & Sales.
“This capacity expansion plan is far more than a matter of production capacity solely. It aims to reorganize sites with new buildings, renew existing facilities and give operations the most advanced equipment in the market, to provide our customers and team members with the technology and the capacity they need to grow in a sustainable way. It is a significant effort and commitment from Hovione to stay ahead of and prepare for future demand.” said Nuno Almeida, Vice-President of Engineering.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.